natgillin/translations-raw huggingface dataset:
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to 
Neželeni učinki so navedeni po padajoči resnosti in njihova pogostnost je opredeljena takole: zelo pogosti: (≥ 1/10); pogosti: (≥ 1/100 do < 1/10); občasni: (≥ 1/1.000 do
However, if levetiracetam treatment is needed during breast-feeding, the benefit/risk of the treatment should be weighed considering the importance of breast-feeding. 
Če je zdravljenje z levetiracetamom v obdobju dojenja potrebno, se mora pretehtati razmerje med koristjo in tveganjem zdravljenja glede na pomembnost dojenja.
You should continue Levetiracetam Teva treatment for as long as your doctor has told you. 
Levetiracetam Teva morate nadaljevati tako dolgo, kot vam je naročil zdravnik.
The dialyser extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite. 
Učinkovitost dializne ekstrakcije levetiracetama je 60 %, primarnega presnovka pa 74 %.
What you need to know before you take Levetiracetam Teva Do not take Levetiracetam Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Levetiracetam Teva Ne jemljite zdravila Levetiracetam Teva
ks = 0.45 in Term infants to 1 year old; ks = 0.55 in Children to less than 13 years and in adolescent female; ks = 0.7 in adolescent male 
ks = 0,45 pri dojenčkih do 1 leta starosti; ks = 0,55 pri otrocih, mlajših od 13 let in pri mladostnicah;
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 
Razdelilna zareza je namenjena le delitvi tablete za lažje požiranje in ne delitvi na dva enaka odmerka.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. 
In vitro študije so pokazale, da levetiracetam vpliva na nivo Ca2+ znotraj nevrona preko delne inhibicije Ca2+ kanalov tipa N in zmanjšanjem sproščanja Ca2+ iz zalog znotraj nevrona.
• Dose in adults and adolescents (from 16 years of age): 
• Odmerjanje pri odraslih in mladostnikih (od 16 leta starosti:)
TEVA UK Ltd Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG UK United Kingdom 
TEVA UK Ltd Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG UK Velika Britanija
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. 
Na začetku zdravljenja ali po povečanju odmerka lahko neželeni učinki, kot na primer zaspanost, utrujenost in omotica, postanejo pogostejši.
Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behaviour Checklist). 
Rezultati, povezani z vedenjskimi in emocionalnimi funkcijami, kažejo pri bolnikih, ki se zdravijo z levetiracetamom, poslabšanje agresivnega obnašanja, ki se izmeri na standardiziran in sistematičen način z uporabo validiranega merskega instrumenta (CBCL - Achenbach Child Behavior Checklist).
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam. 
Predmarketinški podatki iz kliničnih študij, izvedenih pri odraslih, kažejo, da levetiracetam ne vpliva na serumsko koncentracijo drugih protiepileptičnih zdravil (fenitoina, karbamazepina, valprojske kisline, fenobarbitala, lamotrigina, gabapentina in primidona) in da ta protiepileptična zdravila ne vplivajo na farmakokinetiko levetiracetama.
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 % (95 % CI: -7.8 8.2). 
73,0 % bolnikov, ki so se zdravili z levetiracetamom, in 72,8 % bolnikov, ki so se zdravili s karbamazepinom z nadzorovanim sproščanjem (CR), je bilo šest mesecev brez napadov; prilagojena absolutna razlika med zdravljenjema je bila 0,2 % (95 % CI: 7,8-8,2).
What Levetiracetam Teva is and what it is used for What you need to know before you take Levetiracetam Teva How to take Levetiracetam Teva Possible side effects 
Kaj je zdravilo Levetiracetam Teva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Levetiracetam Teva Kako jemati zdravilo Levetiracetam Teva
• on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. 
• za samostojno zdravljenje pri odraslih in mladostnikih od 16. leta starosti z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
Levetiracetam Teva contains Sodium 
Levetiracetam Teva vsebuje natrij
The daily dose must be individualised according to renal function. 
Dnevni odmerek je treba prilagoditi individualno glede na delovanje ledvic.
Swallow Levetiracetam Teva tablets with a sufficient quantity of liquid (e.g. a glass of water). 
Način uporabe Tablete zdravila Levetiracetam Teva zaužijte z dovolj tekočine (npr. s kozarcem vode).
ANNEX II A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO
What Levetiracetam Teva is and what it is used for 
Kaj je zdravilo Levetiracetam Teva in za kaj ga uporabljamo
Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. 
Največjo koncentracijo v plazmi (Cmax) dosežemo 1,3 ure po odmerku.
Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma. 
Neželeni učinki, ki jih niso opazili v kliničnih študijah, opazili pa so jih v študijah pri podganah in v manjši meri pri miših (pri stopnjah izpostavljenosti, ki so bile podobne stopnjam klinične izpostavljenosti) ter imajo možen pomen za klinično uporabo, so naslednji: jetrne spremembe, ki kažejo na prilagoditveni odgovor, kot so povečanje mase jeter in centrolobularna hipertrofija, maščobna infiltracija in zvišanje jetrnih encimov v plazmi.
The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established. 
Varnost in učinkovitost levetiracetama pri otrocih in mladostnikih, mlajših od 16 let, pri samostojnem zdravljenju nista bili dokazani.
• symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function 
• simptome kot so nizek volumen urina, utrujenost, slabost, bruhanje, zmedenost in otekanje nog, gležnjev ali stopal saj so lahko to znaki nenadnega zmanjšanja delovanja ledvic
At 3600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. 
Pri 3600 mg/kg/dan se je samo v eni od dveh študij embriofetalnega razvoja telesna masa plodu rahlo zmanjšala v povezavi z marginalnim povečanjem skeletnih sprememb/manjših anomalij.
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome) 
• široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom)
In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines. 
Poleg tega delno preprečuje inhibicijo GABA in glicinskih kanalov, povzročeno z Zn2+ in β- karbolini.
- The active substance is levetiracetam. 
- Učinkovina je levetiracetam.
In all of the above cases an oral solution should be used. 
V vseh zgoraj naštetih primerih se priporoča uporaba peroralne raztopine.
In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6 % for patients on placebo. 
Delež bolnikov iz zbranih analiz, pri katerih je bilo doseženo 50- ali več odstotno zmanjšanje pogostnosti napadov parcialnega izvora na teden pri stalnem odmerku (12/14 tednov), je bil 27,7 % pri bolnikih, ki so prejemali 1000 mg, 31,6 % pri bolnikih, ki so prejemali 2000 mg in 41,3 % pri bolnikih, ki so prejemali 3000 mg levetiracetama, ter 12,6 % pri bolnikih, ki so prejemali placebo.
If you take more Levetiracetam Teva than you should 
Če ste vzeli večji odmerek zdravila Levetiracetam Teva, kot bi smeli
Very common: may affect more than 1 in 10 people 
Zelo pogosti: pojavijo se pri več kot 1 od 10 oseb
20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 50x1 film-coated tablet 60 film-coated tablets 100 film-coated tablets 120 film-coated tablets 200 film-coated tablets 
20 filmsko obloženih tablet 30 filmsko obloženih tablet 50 filmsko obloženih tablet 50x1 filmsko obložena tableta 60 filmsko obloženih tablet 100 flmsko obloženih tablet 120 filmsko obloženih tablet 200 filmsko obloženih tablet
The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies. 
Odmerki 1800 mg/kg/dan so sprožili izrazito toksičnost pri samicah in zmanjšanje telesne mase zarodka, povezano s povečanjem pogostnosti zarodkov s kardiovaskularnimi/skeletnimi anomalijami.
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day. 
Dve študiji embriofetalnega razvoja pri podganah so izvedli z odmerki 400, 1200 in 3600 mg/kg/dan.
• flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]) 
• gripi podobne simptome in izpuščaj na obrazu, ki se v nadaljevanju razširi in ga spremlja visoka temperatura, zvišane vrednosti jetrnih encimov pri krvnih testih in povečanje števila določenega tipa belih krvnih celic (eozinofilija) ter povečane bezgavke (reakcija na zdravilo z eozinofilijo in sistemskimi simptomi [DRESS]
In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. 
Prav tako jakosti tablet, ki so na voljo, niso primerne za doseganje začetnega odmerka pri otrocih, ki so težki do 25 kg, za uporabo pri bolnikih, ki ne morejo pogoltniti tablet ali za dajanje odmerkov nižjih od 250 mg.
Other medicines and Levetiracetam Teva 
Druga zdravila in zdravilo Levetiacetam Teva
It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. 
Ugotovili so, da se levetiracetam pri populaciji po protokolu ne razlikuje (ni manjvredno) od placeba glede spremembe od začetnih vrednosti rezultatov testiranja spomina in pozornosti (Leiter-R Attention and Memory, Memory Screen Composite).
Contents of the pack and other information What Levetiracetam Teva contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Levetiracetam Teva
However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. 
Vendar pa podatki nakazujejo, da je pri otrocih, ki jemljejo protiepileptična zdravila, ki inducirajo encime, povečan očistek levetiracetama za 20 %.
The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose. 
Zdravnik mora glede na starost, telesno maso in odmerek predpisati najustrežnejšo farmacevtsko obliko, velikost pakiranja in jakost.
A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation). 
Pri odraslih in otrocih so ugotovili pomembno povezavo med koncentracijo v plazmi in slini (razmerje koncentracij v slini/plazmi se giblje med 1 in 1,7 za tableto za peroralno uporabo in za peroralno raztopino 4 ure po odmerku).
Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. 
Levetiracetam in sorodni analogi kažejo vrstni red afinitete za vezavo na sinaptični vezikularni protein 2A, ki korelira z jakostjo protiepileptične zaščite pri mišjem audiogenem modelu epilepsije.
• a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme) 
• kožni izpuščaj, ki lahko tvori mehurčke in po videzu spominja na majhne tarče (na sredini temne pike, obkrožene s svetlejšim delom in s temnim krogom na robu) (multiformni eritem)
*The colourants are: 250 mg film-coated tablets: brilliant blue FCF (E133) and indigotine (E132). 
*Barvila so: 250 mg filmsko obložene tablete: briljantno modro FCF (E133) in indigotin (E132).
• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction 
• šibkost, vrtoglavico ali omotico ali težave z dihanjem, saj so to lahko znaki resne alergijske
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks). 
pri odraslih in mladostnikih, težkih več kot 50 kg: zmanjševanje odmerka za 500 mg dvakrat na dan na vsaka dva tedna do štiri tedne; pri dojenčkih, starejših od 6 mesecev, otrocih in mladostnikih s telesno maso manj kot 50 kg: zmanjšanje odmerka ne sme preseči 10 mg/kg dvakrat na dan vsaka dva tedna; pri dojenčkih (mlajših od 6 mesecev): zmanjšanje odmerka ne sme preseči 7 mg/kg dvakrat na dan vsaka dva tedna).
• decreased number of blood platelets, decreased number of white blood cells; 
• zmanjšano število krvnih ploščic, zmanjšano število belih krvnih celic • zmanjšanje telesne mase, povečanje telesne mase
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. 
Poleg tega je bilo v študijo o varnosti v obdobju po začetku trženja zdravila vključenih 101 dojenčkov, mlajših od 12 mesecev.
Transparent PVC/PVdC - aluminium blisters. 
Prozorni pretisni omot iz PVC/PVdC-aluminija.
• Levetiracetam Teva is used as a chronic treatment. 
• Zdravilo Levetiracetam Teva se uporablja za dolgotrajno zdravljenje.
• Levetiracetam Teva is not indicated in children and adolescents below 16 years on its own (monotherapy). 
• Zdravilo Levetiracetam Teva pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija).
The maximum dose is 1500 mg twice daily. 
Največji odmerek je 1500 mg dvakrat na dan.
• Dose in infants (1 month to 23 months), children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg: 
• Odmerjanje pri dojenčkih (od 1 meseca do 23 mesecev), otrocih (od 2 do 11 let) in mladostnikih (od 12 do 17 let), lažjih od 50 kg:
Each Levetiracetam Teva 250, 500, 750, 1,000 mg film-coated tablet contains 250, 500, 750, 1,000 mg levetiracetam. 
Ena 250, 500, 750, 1.000 mg filmsko obložena tableta zdravila Levetiracetam Teva vsebuje 250, 500, 750, 1.000 mg levetiracetama.
The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session. 
Frakcijska odstranitev levetiracetama med tipično 4-urno dializo je bila 51 %.
The tablet formulation is not adapted for use in infants and children under the age of 6 years. 
Farmacevtska oblika tableta ni primerna za uporabo pri dojenčkih in otrocih, mlajših od 6 let.
If stopping treatment, Levetiracetam Teva should be discontinued gradually to avoid an increase of seizures. 
Pri zdravilu Levetiracetam Teva je treba zdravljenje opustiti postopoma, da se število napadov ne bi povečalo.
• as an add-on to other antiepileptic medicines to treat: ■ partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age ■ myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy ■ primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause). 
■ parcialnih napadov z generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca dalje ■ miokloničnih napadov (kratki, nenadni trzaji mišice ali skupine mišic) pri odraslih in mladostnikih od 12. leta starosti z juvenilno mioklonično epilepsijo ■ primarno generaliziranih tonično-kloničnih napadov (veliki napadi, vključno z izgubo zavesti) pri odraslih in mladostnikih od 12. leta starosti z idiopatsko generalizirano epilepsijo (oblika epilepsije, za katero se domneva, da je genetskega izvora)
As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam. 
Tako kot pri odraslih tudi pri pediatričnih bolnikih, ki so prejemali do 60 mg/kg/dan levetiracetama, ni jasnih dokazov o klinično značilnem medsebojnem delovanju z zdravili.
In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses. 
V tej študiji je bil odmerek levetiracetama za odrasle in mladostnike 3.000 mg na dan, za otroke pa 60 mg/kg/dan, razdeljen na dva odmerka.
Therefore, there is no need for plasma level monitoring of levetiracetam. 
Koncentracije levetiracetama v plazmi zato ni treba kontrolirati.
If you stop taking Levetiracetam Teva 
Če ste prenehali jemati zdravilo Levetiracetam Teva
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). 
Učinkovitost levetiracetama je bila dokazana v 24-tedenski dvojno slepi, s placebom nadzorovani študiji, ki je vključevala odrasle, mladostnike in omejeno število otrok z idiopatsko generalizirano epilepsijo s primarno generaliziranimi tonično-kloničnimi (PGTC) napadi pri različnih sindromih (juvenilna mioklonična epilepsija, juvenilna epilepsija z absencami, otroška epilepsija z absencami ali epilepsija z grand mal napadi pri prebujanju).
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6) and epoxide hydroxylase activities. 
In vitro so pokazali, da levetiracetam in njegov primarni presnovek ne zavirata aktivnosti glavnih izooblik človeškega jetrnega citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 in 1A2),
CLcr (ml/min/1.73 m2) = CLcr (ml/min)__ x 1.73 
CLcr (ml/min/1,73 m2) = CLcr (ml/min) x 1,73 BSA bolnika (m2)
For adult patients, refer to the following table and adjust the dose as indicated. 
Sklicujoč se na spodnjo preglednico se odmerek za odrasle bolnike prilagodi kot je navedeno.
For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. 
Pri otrocih z ledvično okvaro je treba odmerek levetiracetama prilagoditi glede na delovanje ledvic,
The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume. 
Tako levetiracetam kot njegov primarni presnovek se ne vežeta pomembno na beljakovine v plazmi Volumen porazdelitve levetiracetama je približno 0,5 do 0,7 l/kg, kar je blizu vrednosti celotnega volumna vode v telesu.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. 
Učinkovitost levetiracetama za samostojno zdravljenje je bila dokazana v dvojno slepi študiji z vzporednimi skupinami, ki dokazuje, da levetiracetam po učinkovitosti ni nič slabši od karbamazepina z nadzorovanim sproščanjem (CR), pri 576 bolnikih, starih 16 let ali več, z na novo ali nedavno diagnosticirano epilepsijo.
Infection 
• okužba
(4)Following dialysis, a 3.5 to 7 mg/kg supplemental dose is recommended. 
(4)Po dializi je priporočljiv dodatni odmerek od 3,5 do 7 mg/kg.
Tablet core: maize starch, povidone, croscarmellose sodium and magnesium stearate. 
Jedro tablete: koruzni škrob, povidon, premreženi natrijev karmelozat in magnezijev stearat.
The possible side effects of an overdose of Levetiracetam Teva are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma. 
Možni neželeni učinki pri prevelikem odmerjanju zdravila Levetiracetam Teva so zaspanost, agitiranost, agresivnost, zmanjšana budnost, upočasnitev dihanja in koma.
There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. 
Obstajajo posamezna poročila o zmanjšani učinkovitosti levetiracetama pri sočasni uporabi makrogola, ki je osmotsko odvajalo, in peroralnega levetiracetama.
Levetiracetam Teva is used: 
Zdravilo Levetiracetam Teva se uporablja:
10 to 20 mg/kg once daily (3) (5) 
10 do 20 mg/kg enkrat na dan (3) (5)
Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. 
Učinkovitost levetiracetama je bila dokazana v dvojno slepi, s placebom nadzorovani 16-tedenski študiji pri bolnikih od 12 leta starosti, z idiopatsko generalizirano epilepsijo z miokloničnimi napadi pri različnih sindromih.
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day. 
Štiri študije embriofetalnega razvoja pri kuncih so izvedli z odmerk 200, 600, 800, 1200 in
(5)Following dialysis, a 5 to 10 mg/kg supplemental dose is recommended. 
(5)Po dializi je priporočljiv dodatni odmerek od 5 do 10 mg/kg.